MODELING APPROACH
Objective: We develop a framework for stratified cost-effectiveness analysis using individual-based discrete-event simulations that allow for the representation of heterogeneous patient populations, and which can be used to evaluate the cost-effectiveness of genetic testing in different patient groups.
Conclusion:
In each study, we used a simulation model to identify a subpopulation based on age and clinical risk, for whom we used genetic testing to find intensified prevention measures, which was optimally cost-effective. As more genetic tests become available, this method can be used to identify screening strategies that maximize costeffectiveness.
In each study, we used a simulation model to identify a subpopulation based on age and clinical risk, for whom we used genetic testing to find intensified prevention measures, which was optimally costeffective.
As more genetic tests become available, this method can be used to identify screening strategies that maximize cost-effectiveness.
We develop a framework for stratified costeffectiveness analysis using individual-based discrete-event simulations that allow for the representation of heterogeneous patient populations, and which can be used to evaluate the cost-effectiveness of genetic testing in different patient groups.
Genetic testing and MRI screening for breast cancer
A number of single-nucleotide polymorphism (SNPs) have been found which confer a moderately increased risk of breast cancer.
At age 40 or 50, women received an estimate of their lifetime risk of breast cancer using the Gail risk test, based on life and family history.
If their clinical risk fell within a specified range, they also received a genetic test based on 7 SNPs, which modified their risk estimate.
In the control arm, women received the Gail risk test only.
In both arms, women with a risk greater than 20% received annual MRI screening of the breast, while other women received annual mammography.
Genetic screening for breast cancer risk was most cost-effective in women age 40 with a lifetime clinical risk of 16-28%.
The Discrete Event Simulation Model consists of two components:
Natural History
Mutation distributions
Correlations between mutation and other risk factors (e.g. family history)
Cancer incidence, progression, and mortality
Healthcare interventions
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Genetic screening identifies candidates for intensified cancer screening and prevention.
Due to the high cost of genetic testing, it is important to identify patients who are most likely to benefit.
Doing so using clinical trials is prohibitively expensive; thus a mathematical modeling approach is required. 
GENERAL APPROACH
The genetic screening strategy consists of three steps:
Benefit-risk assessment, in which patients are assessed for risk of carrying mutations and potential benefits from genetic testing Genetic testing, in which qualified patients within an optimal risk bracket are given the appropriate tests
Intervention, in which patients are given preventative care based on the results from the genetic tests.
CASE 1
Genetic screening for Lynch Syndrome
Lynch Syndrome is an autosomal, dominant germline mutation conferring elevated risk of colorectal and endometrial cancer.
A simulated patient population was generated, including 5-generation genealogies for simulated patients.
Risk of carrying Lynch Syndrome was evaluated in simulated patients based on demographics and family history using the PREMM126 model, at age 20, 25, 30, 35, or 40.
Patients received genetic testing if their risk fell above a threshold (0%, 2.5%, 5%, or 10%).
Patients testing positive for Lynch Syndrome were screened annually with colonoscopy, endometrial biopsy, and transvaginal ultrasound, while patients testing regularly received standard screening according to guidelines.
In the control arm, patients received a genetic test if they had a Lynch Syndromeassociated cancer, and if they tested positive, genetic testing was extended to atrisk relatives, but no primary genetic testing occurred.
Primary screening for Lynch Syndrome was cost-effective for patients at least 25 years old and with a risk of at least 5%.
CASE 3
Genetic testing and chemoprevention for breast cancer
White women ages 40 -69 with a history of benign breast biopsy received the Gail risk test, followed by the 7SNP genetic test if their five-year risk fell between a given cutoff value (1.0%, 1.1%, 1.2%, 1.3%, 1.4%, and 1.5%) and 1.66%.
In both arms, women whose five-year risk was greater than 1.66% received chemoprevention using tamoxifen therapy.
Genetic testing to inform chemoprevention decisions was found to be cost-effective for women with a five-year risk of 1.2-1.66%, and most cost-effective for women ages 50-59. Non-Dominated Dominated
